← All trials
NCT05513391
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2022
- Primary completion
- Oct 13, 2023
- Completion date
- Oct 13, 2023
- First posted
- Aug 24, 2022
- Last posted
- Nov 21, 2022
- Enrollment
- 1412
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.